Key facts
- NeuroQore’s last known valuation is $10.6M (Sep 2025).
- It has raised $1.7M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Jul 2025.
- Notable investors include SOSV, IndieBio, Texas Medical Center, Federal Economic Development Agency for Southern Ontario, Ontario Brain Institute.
- NeuroQore has filed 1 Form D with the SEC, most recently Sep 2025 ($1.5M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for NeuroQore
Funding rounds
1 roundsAbout NeuroQore
Developer of neuromodulation treatment systems designed to address depressive disorder and suicidality. The company's systems include a semiconductor switch that emits a novel magnetic pulse, enabling patients to overcome neurobehavioral conditions and have improved quality of life.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2012
- Employees
- 2
- Website
- neuroqore.com/
- Ownership
- Privately Held (backing)
NeuroQore doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroQore shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroQore in its N-PORT filings yet. We sweep new filings monthly.